NST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense
The study is set to be completed in January of 2021, following 12-months dosing.
Clinical trials, studies, data, and updates reported in Medical Device News Magazine.
- Go to the previous page
- 1
- …
- 537
- 538
- 539
- 540
- 541
- 542
- 543
- …
- 584
- Go to the next page